Richardson Electronics (RELL) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
8 Jul, 2026Executive summary
Q1 FY25 net sales rose 2.2% year-over-year to $53.7 million, driven by strong growth in Green Energy Solutions (GES) and Healthcare, offsetting declines in PMT and Canvys.
Gross margin declined to 30.6% from 32.8% year-over-year, mainly due to unfavorable product mix and under absorption in manufacturing.
Operating income was $0.3 million, down from $1.5 million in the prior year; net income was $0.6 million ($0.04 per diluted share), compared to $1.2 million ($0.09 per share) last year.
Positive operating cash flow was generated for the second consecutive quarter; cash and cash equivalents stood at $23.0 million with no debt at quarter-end.
Backlog at quarter-end was $137.4 million, with expectations for continued strength through FY25.
Financial highlights
EBITDA was $1.7 million (3.1% of sales), down from $2.6 million (5.0%) year-over-year.
Capital expenditures were $0.9 million, mainly for facilities and IT.
$0.9 million paid in cash dividends; no debt on a $30 million credit line.
SG&A expenses were $16.1 million, or 30.0% of net sales, flat as a percentage of sales year-over-year.
Effective tax rate was 9.0%, down from 23.7% in the prior year, reflecting geographic income mix and increased R&D credits.
Outlook and guidance
Management expects improved gross margins and sales growth in the second half and full FY25, especially in GES and Healthcare.
Backlog is increasing, especially in GES and semiconductor wafer fab equipment.
Anticipates new product launches in green energy and continued growth in key segments through FY25.
Expects improved gross margin as manufacturing demand rises and under absorption decreases.
Management believes liquidity and cash flow from operations will be sufficient for capital and working capital needs over the next twelve months.
Latest events from Richardson Electronics
- Q4 net sales up 27.6%, record backlog, and strong outlook with dividend declared.RELL
Q4 202623 Jul 2026 - Q2 FY25 sales up 12.1% to $49.5M, led by 129% GES growth and improved margins.RELL
Q2 20258 Jul 2026 - Q1 FY2026 net income tripled to $1.9M on 1.6% sales growth and improved margins.RELL
Q1 20268 Jul 2026 - Q2 FY26 sales up 5.7% to $52.3M, GES up 39%, backlog $135.7M, $0.06 dividend, no debt.RELL
Q2 202613 Apr 2026 - Q3 FY26 delivered 3.1% sales growth, profitability, and record backlog, led by PMT segment gains.RELL
Q3 202612 Apr 2026 - Sales and profits fell in 2024, but margin, cash flow, and backlog support a positive 2025 outlook.RELL
Q4 20242 Feb 2026 - Q3 net sales up 2.7% YoY, strong PMT/Canvys, $4.9M Healthcare loss, cash $36.7M, no debt.RELL
Q3 202516 Jan 2026 - Shareholders will vote on director elections, auditor ratification, compensation, and capital structure changes.RELL
Proxy Filing1 Dec 2025 - Proxy seeks approval for director elections, auditor, compensation, and share increases.RELL
Proxy Filing1 Dec 2025